№ files_lp_3_process_9_52026
File format: docx
Character count: 12616
File size: 46 KB
This document includes various standard endpoints for clinical safety and pharmacological studies on a specific drug compound, detailing different categories and parameters for observations and measurements across various testing protocols.
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Context description:
This document provides email templates and guidelines for communicating with end users about upcoming changes related to Duo Security’s Trusted Endpoints enforcement and Duo Mobile app requirements.
Source of adaptation:
Code of Practice for the Housing and Care of Laboratory Mice, Rats, Guinea Pigs and Rabbits, Agriculture Victoria
Institution:
Griffith University
Committee:
Animal Ethics Committee (AEC)
Facility:
Biosciences Resources Facility
Document type:
Monitoring scoresheets and clinical welfare assessment forms
Purpose:
Submission with AEC application and annual reports
Retention requirement:
Records kept for 7 years after project completion
Scope:
Laboratory mice, rats, guinea pigs and rabbits
Includes:
Daily Monitoring Scoresheet; Clinical Welfare Scoresheet (Example 2 and 3); Post-Surgery Scoresheet
Reference cited:
Morton, D.B. (1997) A scheme for the recognition and assessment of adverse effects in animals. In Developments in animal and veterinary sciences, 27. Animal Alternatives, Welfare and Ethics. Elsevier Science B.V.
Contact details:
Animal Ethics Coordinator [email protected]
Note:
; Biosciences Resources Facility Manager telephone 5552 8308; Animal Ethics Coordinator telephone 3735 6648
Year:
2023
Region / City:
Manchester, UK
Subject:
Maternity Care, Health Research
Document Type:
Research Protocol
Institution:
University of Manchester
Author:
Professor Alexander Heazell
Target Audience:
Researchers, NHS Staff, Policy Advisors
Period of Validity:
November 2023 - May 2025
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2021
Region / City:
N/A
Theme:
Clinical outcomes, Radiographic analysis
Document Type:
Research table
Author:
Banger, Bell, Blyth, Çabuk, Clement, Cool, FuJun, Gilmour, Hansen, Katherine, Kayani, Lonner, Maritan, Motesharei, Park, St Mart, Tan, Thilak, Wong, Wu, Yin
Target Audience:
Researchers, Medical professionals
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Year:
2021
Region:
United States
Subject:
Patent law, pharmaceutical patents, multiple sclerosis treatment
Document type:
Legal case analysis
Court / institution:
Federal Circuit, U.S. District Court for the Northern District of West Virginia
Author:
Dennis Crouch
Key parties:
Biogen Int’l GMBH, Mylan Pharma Inc.
Patent number:
US 8,399,514
Drug involved:
Dimethyl fumarate (DMF)
Legal issue:
Written description requirement
Date of decision:
November 30, 2021
Judges involved:
Judge Keeley, Judge Reyna, Judge Hughes, Judge O’Malley
Relevant prior art:
Original 2007 provisional application
Year:
2019
Region / City:
United States
Topic:
Immigration Services
Document Type:
Instruction Manual
Organization:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services
Target Audience:
Individuals applying for immigration benefits
Effective Period:
Ongoing, with periodic updates
Approval Date:
10/15/2019
Date of Changes:
10/15/2019
Version:
1.01.00
Date:
12/14/2017
Originator:
K. Hutchinson
Description of Change:
Added T3 and T17 region fields, Deleted old region fields, Administrative changes
Scope:
One table for all FYs
Frequency of processing:
Provided from the POC only as changes are made to the list
Pharmacy ID (NCPDP) Format:
Char 7
Pharmacy Name Format:
Char 40
DMIS ID Format:
Char 4
Pharmacy NPI (formerly NPI Type 2) Format:
Char 10
Record layout and content:
All fields are variable length and delimited by “|”
Data Manipulation:
Using VLOOKUP, map NCPDP # to DMISID
Updates:
Updates to the table are no more than once a month
Note:
Data joins performed in M2
Region / city:
N/A
Type of document:
Specification document
Target audience:
Professionals involved in the MHS Mart system
Date of approval:
12/14/2017
Context:
Specification document for Pharmacy ID (NCPDP) Reference Table in MHS Mart (M2), detailing data formats, mappings, and updates procedures.
Year:
2024
Region / City:
United States
Topic:
Immigration
Document Type:
Instructional Manual
Agency:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services
Target Audience:
Individuals applying for Form I-192
Effective Period:
02/02/2024 - 02/28/2026
Approval Date:
02/02/2024
Date of Changes:
02/02/2024
Year:
2018
Region / City:
Long Beach, CA
Subject:
Commercial supplies and services for auditorium table repairs
Document Type:
Combined Synopsis/Solicitation
Agency / Organization:
Department of Veterans Affairs, Network Contracting Office 22
Author:
John Harrison, Contracting Specialist
Target Audience:
Service-disabled veteran-owned small businesses (SDVOSBs) and veteran-owned small businesses (VOSBs)
Period of validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Context:
Combined synopsis/solicitation notice for requesting quotes on auditorium table repairs for the VA Loma Linda Healthcare System.
Year:
2024
Region / City:
Not specified
Topic:
Postmortem MRI, Fetal MRI, Radiological Autopsy
Document Type:
Supplementary Material
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
1991-2014
Region / City:
UK
Topic:
Labour Market Transitions, Demographic Analysis
Document Type:
Research Supplement
Author:
Not specified
Target Audience:
Researchers, Policy Analysts, Demographers
Period of Validity:
1991-2014
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2025
Region / city:
EU
Topic:
Health Technology Assessment
Document Type:
Guidance
Organization / Institution:
HTA CG
Author:
European Commission
Target audience:
Professionals in Health Technology Assessment
Validity period:
From 28 NOVEMBER 2025
Approval date:
28 NOVEMBER 2025
Amendment date:
Not specified
Year:
2023
Region / City:
United States
Theme:
Immigration
Document Type:
Form
Institution:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services (USCIS)
Target Audience:
Applicants for refugee status and their legal representatives
Effective Period:
Until 08/31/2025
Approval Date:
08/10/2022
Modification Date:
10/17/2023
Year:
2026
Region / City:
Goa, India
Topic:
Data Collection & Consumption
Document Type:
Technical Report
Organization:
3GPP
Author:
Xiaonan Shi, Jean Trakinat
Target Audience:
3GPP members, 6G system developers
Period of Validity:
Ongoing
Approval Date:
TBD
Date of Modifications:
February 2026
Agenda Item:
x.x
Document for:
Approval
Contact:
Xiaonan Shi ([email protected]
Note:
)
Abstract:
Provides initial Table 14.1.5-3 for consolidation discussions on 6G data collection and consumption mechanisms.
Context:
This document is a technical report for discussion and approval of proposed requirements for data collection and consumption within 6G systems, focusing on privacy, security, and data processing.
Year:
2025
Region / City:
Eastern Atlantic and Mediterranean
Subject:
Bluefin tuna fishing and capacity management
Document type:
Template
Organization / Institution:
ICCAT Secretariat
Author:
ICCAT Secretariat
Target audience:
Panel 2 members, European Union, fishing industry stakeholders
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Contextual description:
Draft template for the capacity table related to bluefin tuna fishing, farming, and management plans, with a focus on quota adjustments and fleet capacity.
Note:
Study Summary 1.1 Please provide a brief summary of the study in the table below. A complete description of the study with detailed information should be provided in the body of the protocol. For sections not applicable to the study, mark them as N/A. Study Title Study Design Primary Objective/Purpose Secondary Objective(s)/Purposes Research Intervention(s) ClinicalTrials.gov NCT # Study Population Sample Size Study Duration for individual subjects Study Specific Abbreviations/ Definitions
Background 3.1 Provide the scientific or scholarly background for, rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge. :
this section should be limited to only information directly related to the research questions and objectives. Do not include your full dissertation proposal. 3.2 Describe any relevant preliminary data (e.g. pilot data).
Procedures Involved 5.1 Describe and explain the study design. 5.2 Please select the methods that will be employed in this study (select all that apply):
☐ Audio/Video Recording ☐ Psychophysiological Recording ☐ Behavioral Interventions ☐ Record Review - Educational ☐ Behavioral Observations and Experimentations ☐ Record Review - Employee ☐ Deception ☐ Record Review- Medical ☐ Focus Groups ☐ Record Review - Other ☐ Interviews ☐ Specimen Collection or Analysis ☐ Investigational Medical Device – (e.g. Medical Mobile Applications) ☐ Surveys and/or Questionnaires ☐Psychometric Testing ☐ Other Social-Behavioral Procedures Provide a description of all research procedures being performed and when they are performed. (Upload any surveys, questionnaires, interview scripts, focus group scripts, debriefing scripts, psychometric tests, stimulus materials, intervention manuals, and data collection forms on the Local Site Documents page in the IRB application.) 5.3 Describe the procedures or interventions that are going to be conducted as part of the research project, but that would have been conducted anyway, even if the research was not occurring (i.e. standard of care procedures, activities that would occur in a classroom). 5.4 Describe the procedures performed to lessen the probability or magnitude of risks of items selected in 5.2.5. 5 If accessing or collecting existing data, describe: The data that will be collected during the study (e.g. demographics, medical history, etc.). Attach the data capture sheet(s) on the Local Site Documents page in the IRB application. How the data will be obtained, including how you have the authority to access the data. The source or location of the data (e.g. USF Epic, TGH Epic, Hillsborough County School records, CANVAS records, publicly available databases, etc.). 5.6 If collecting and/or analyzing biological specimens, describe: How the biological specimens will be or have been collected. How the biological specimens will be stored. How long the biological specimens will be stored. How the biological specimens will be used. The laboratories that will be used. Whether the collected biological specimens will undergo genetic testing. If so, indicate if this study is part of a Genome Wide Association Study (GWAS) and whether the data will be forwarded to the NIH dbGaP. 5.7 If there are plans for long-term follow-up (once all research related procedures are complete), what data will be collected during this period.
Data and Specimen Storage for Future Research 6.1 If data or specimens will be banked for future research studies, describe where the data or specimens will be stored, how long it/they will b:
the process to request a release, approvals required for release, who can obtain data or specimens, and the data to be provided with specimens.
Year:
2023
Region / city:
Singapore
Topic:
Pharmaceutical manufacturing and regulatory requirements
Document type:
Regulatory guideline
Organization:
Health Sciences Authority
Author:
Health Sciences Authority
Target audience:
Pharmaceutical manufacturers, regulatory professionals
Validity period:
N/A
Approval date:
N/A
Amendment date:
N/A
Year:
2026
Region / City:
Singapore
Subject:
Pharmaceutical Manufacturing and Regulatory Compliance
Document Type:
Regulatory Guidelines
Organization:
Health Sciences Authority (HSA)
Author:
Health Sciences Authority
Target Audience:
Pharmaceutical Manufacturers, Regulatory Affairs Professionals
Period of Validity:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Institution:
University of Technology Sydney
Program:
Master of Speech Pathology
Document type:
Prerequisite assessment instructions and assessment table
Intake year:
2024
Applicant categories:
Domestic applicants; International applicants
Assessment stage:
Pre-assessment prior to applications opening (domestic only)
Submission timing:
With application after applications open
Submission format:
Word document (.docx)
File naming convention:
LASTNAME-master-speech-pathology-prerequisite-table.docx
Prerequisite subjects:
Human Anatomy; Human Physiology
Level of study required:
Tertiary level
Prerequisite completion timeframe:
Within the past 10 years
Concurrent study:
Not permitted
Academic review cycle:
Annual
Assessment authority:
Academic team
Source type:
University admissions requirements document defining eligibility criteria, submission conditions, and academic content standards for prerequisite subjects for entry to a postgraduate degree.
Date:
12 May 2025
Document Number:
EMA/152360/2016 rev.1
Modules:
2.5, 2.7.1, 2.7.2, 2.7.3, 2.7.4, 5.3.x.x
Type:
Regulatory submission template
Purpose:
Clinical overview, biopharmaceutical studies, clinical pharmacology, efficacy, safety, CSR body, CSR appendices
Applicant/MAH:
Not specified
Regulatory Agency:
European Medicines Agency
Confidentiality Guidance:
Annex 3 of POLICY/0070
Period:
2025